Research area · Why evidence doesn't transfer

Peptide blends: one vial, no shared evidence

Blends combine two or more peptides in one vial. A study of one compound says nothing about a mix, so a blend has only the evidence from studies of that blend. If you searched for “peptide stack”, this is the page for it; we use the word blend.

  • Evidence grade or review status for every compound
  • Sources listed on every page
  • US and sport status, dated
3 compoundsEarly human (topical) · Preclinical
Updated Nov 2026Dated on every page
BPC-157 TB-500 GHK-CU
Short answerResearch area · Updated 18 Nov 2026

Blends combine two or more peptides in one vial. A study of one compound says nothing about a mix, so a blend has only the evidence from studies of that blend. No controlled human study has tested BPC-157 with TB-500 or CJC-1295 with ipamorelin, and we found no published study, in any species, of the mixes sold as GLOW or KLOW.

The research so far

Does research on single peptides apply to blends?

Evidence attaches to what was studied. A study of one compound says nothing about a pair or a blend, so each compound is graded on its own.

People often cite two 2006 placebo-controlled studies for "CJC-1295 with ipamorelin". Both tested CJC-1295 alone, in the long-acting form the paper describes; they did not test forms sold as "no DAC". Ipamorelin's human studies also tested it on its own. No human study tested the pair. [1] [5] [2] [6] [4]

We found no published study, in any species, that tested the mixes sold as GLOW or KLOW. [4]

The blends people ask about

The "Wolverine" blend

A name sellers use for a blend, not a compound. Each ingredient is graded on its own, and no controlled human study has tested BPC-157 and TB-500 together. Only a lab report for that batch shows what was in the tested sample.

Recovery research

GLOW and KLOW blends

We found no published study, in any species, that tested the mixes sold under these names. The topical evidence for GHK-Cu does not carry over to a mixed vial.

Skin research

CJC-1295 + ipamorelin

The two 2006 placebo-controlled studies often cited for the pair tested CJC-1295 alone, in the long-acting form the paper describes; they did not test forms sold as "no DAC". Ipamorelin's human studies also tested it on its own. No human study tested the pair. Both are named on WADA's 2026 Prohibited List (S2).

Peptides in sport
Evidence grades

How far has the research on each ingredient gone?

Pick a compound to see the highest rung reached, from cell study to approval.

Cell studies
—
Animal studies
—
Human pilot / case series
—
Controlled human trials
—
Regulatory approval
—
Highest rung reached
—

How we grade evidence

What doesn’t the research on peptide blends show?

Saying what we don't know is part of the evidence.

Any effect of a blend in people: no controlled human study has tested any of the mixes on this page.

That a blend is equivalent to its parts: stability and purity in a mixed vial are separate questions for the lab report.

Are BPC-157, TB-500 and GHK-Cu FDA-approved medicines? US and sport status

As of November 2026. See the full tracker and the changelog.

CompoundFDA approval503A compounding (2026)WADA (2026 List)
BPC-157Not approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S0, named)
TB-500Not approvedFDA advisory committee voted for listing (Jul); HHS enforcement-discretion policy (Oct); no rule yetProhibited (S2, named)
GHK-CuNot approvedInjectable form formerly FDA Category 2; nomination withdrawn (FDA list, current 22 Apr 2026); not in the July reviewNot named; S0 covers unapproved substances

Worth knowing

Research use only

None of the compounds on this page is an FDA-approved medicine. Nothing on this page is medical advice or describes use in people.

What research use only means

No doses, ever

We publish no doses, protocols, or cycles for people, on any page.

Why we publish no doses

How we grade evidence

Grades follow study design: cell and animal studies (preclinical), small human studies, then controlled human trials, with approval tracked separately. A grade is not a promise of any effect.

Evidence grades

Questions people ask

Is there evidence for the Wolverine blend?

Not in people. Each compound in a blend is graded on its own, and no controlled human study has tested BPC-157 and TB-500 together.

What should a lab report for a blend show?

Identity and purity for each peptide in the vial, matched to the batch number. A single purity figure for the whole mix does not tell you that.

Sources

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PMID 16352683. pubmed.ncbi.nlm.nih.gov/16352683/
  2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–1416. PMID 10496658. doi.org/10.1023/A:1018955126402
  3. World Anti-Doping Agency. Prohibited List 2026 (in force 1 January 2026) and 2027 (in force 1 January 2027). www.wada-ama.org/en/prohibited-list
  4. PubMed and ClinicalTrials.gov searches for human studies of BPC-157 with TB-500 and of CJC-1295 with ipamorelin, and PubMed searches for any study of GHK-Cu with BPC-157, TB-500 or KPV, 17–18 November 2026: no controlled human study of either pair, and no study that tested the GLOW or KLOW mixes, found. pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+AND+ipamorelin
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID 15817669. pubmed.ncbi.nlm.nih.gov/15817669/
  6. Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. PMID 25331030. pubmed.ncbi.nlm.nih.gov/25331030/
  7. Delcourt V, et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458–464. PMID 36482504. pubmed.ncbi.nlm.nih.gov/36482504/

Start with the evidence

Every page sourced and dated, including what the research does not show.

Open the research library
Written by 6AM Research. Drafted with AI from published studies, trial registries, and regulator documents, plus press reports where marked. Every page lists its sources and is dated. Editorial policy · Corrections
Education only. Nothing here is medical advice or describes use in people. Research use only